Lancet Diabetes & Endocrinology r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname The Lancet Diabetes & Endocrinology Volume 7 Issue 8 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tuñón, J, White, H D, Zeiher, A M, Schwartz, G G, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tuñón, J, White, H D, Zeiher, A M, Schwartz, G G, Steg, P G & ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Lancet diabetes & endocrinology ODYSSEY OUTCOMES Committees and Investigators 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes : a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes and Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 Ray, K K, Colhoun, H M, Szarek, M, Baccara-Dinet, M, Bhatt, D L, Bittner, V A, Budaj, A J, Diaz, R, Goodman, S G, Hanotin, C, Harrington, R A, Jukema, J W, Loizeau, V, Lopes, R D, Moryusef, A, Murin, J, Pordy, R, Ristic, A D, Roe, M T, Tunon, J, White, H D, Zeiher, A M, Schwartz, G S, Steg, P G, Schwartz, G G, Steg, P G, ODYSSEY OUTCOMES Committees and Investigators, Clemmensen, P, Gislason, G, Nielsen, P K, Davidsen, F, Andersen, D, Jeppesen, J & Videbæk, L 2019, ' Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial ', The Lancet Diabetes & Endocrinology, vol. 7, no. 8, pp. 618-628 . https://doi.org/10.1016/S2213-8587(19)30158-5 r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA Lancet Diabetes and Endocrinology, 7(8), 618-628. ELSEVIER SCIENCE INC
The Lancet The Lancet, Elsevier, 2019, 394 (10204), pp.1169-1180. ⟨10.1016/S0140-6736(19)31887-2⟩ The Lancet (London), 394, 1169-1180 Bhatt, D L, Steg, P G, Mehta, S R, Leiter, L A, Simon, T, Fox, K, Held, C, Andersson, M, Himmelmann, A, Ridderstråle, W, Chen, J, Song, Y, Diaz, R, Goto, S, James, S K, Ray, K K, Parkhomenko, A N, Kosiborod, M N, McGuire, D K, Harrington, R A & THEMIS Steering Committee and Investigators 2019, ' Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial ', Lancet, vol. 394, no. 10204, pp. 1169-1180 . https://doi.org/10.1016/S0140-6736(19)31887-2 The Lancet (London), 394, 10204, pp. 1169-1180
NEW ENGLAND JOURNAL OF MEDICINE r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname
The New England Journal of Medicine, 366, 20-33 Tricoci, P, Huang, Z, Held, C, Moliterno, D J, Armstrong, P W, Van de Werf, F, White, H D, Aylward, P E, Wallentin, L, Chen, E, Lokhnygina, Y, Pei, J, Leonardi, S, Rorick, T L, Kilian, A M, Jennings, L H K, Ambrosio, G, Bode, C, Cequier, A, Cornel, J H, Diaz, R, Erkan, A, Huber, K, Hudson, M P, Jiang, L, Jukema, J W, Lewis, B S, Lincoff, A M, Montalescot, G, Nicolau, J C, Ogawa, H, Pfisterer, M, Prieto, J C, Ruzyllo, W, Sinnaeve, P R, Storey, R F, Valgimigli, M, Whellan, D J, Widimsky, P, Strony, J, Harrington, R A, Mahaffey, K W, TRACER Investigators & Rasmussen, L H 2012, ' Thrombin-receptor antagonist vorapaxar in acute coronary syndromes ', The New England Journal of Medicine, vol. 366, no. 1, pp. 20-33 . https://doi.org/10.1056/NEJMoa1109719 Recercat. Dipósit de la Recerca de Catalunya instname Dipòsit Digital de la UB Universidad de Barcelona The New England Journal of Medicine, 366, 1, pp. 20-33